Why the study?
Does adiponectin treatment reduce carotid atherosclerotic plaque formation in ApoE-/- mice?
Does adiponectin treatment reduce carotid atherosclerotic plaque formation in ApoE-/- mice?
Adiponectin reduces atherosclerosis progression in a mouse model by inhibiting iNOS and diminishing oxidative and nitrative stress.
Adiponectin gene therapy may attenuate murine atherosclerosis; leaves open translation to human plaque progression.
Adiponectin (APN) is an important anti‑atherogenic adipocytokine. The aim of the present study was to investigate the role of adiponectin in atherosclerotic plaque formation and clarify its mechanisms. An atherosclerosis model was induced by in vivo perivascular constrictive silica collar placement on the left common carotid arteries in male apolipoprotein E‑deficient (ApoE‑/‑) mice. All of the mice were fed a high‑fat diet, and divided into phosphate‑buffered saline, adenovirus (Ad)‑β‑galactosidase and Ad‑APN treatment groups. Compared with treatment of Ad‑β‑gal or PBS, Ad‑APN treatment markedly reduced inducible nitric oxide synthase (iNOS) protein expression, decreased in nitric oxide/superoxide production, blocked peroxynitrite formation and reversed the progression of atherosclerotic lesions. Adiponectin may be a natural molecule that reduces atherosclerosis by inhibiting iNOS and consequently diminishing oxidative/nitrative stress.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: